{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:12:12Z","timestamp":1751688732114,"version":"3.41.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The use of propranolol in the treatment of panic attacks has historically been widespread. However, there is insufficient precise evidence regarding the combination of propranolol with sertraline in this context. Panic attacks are a common health issue among women, significantly affecting their personal and social lives. Therefore, this study aimed to determine the effect of sertraline, with or without propranolol, on the severity of panic attack symptoms and depressive symptoms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This randomized controlled clinical trial included 60 women who attended a specialized university clinic in Tabriz. Participants were randomly assigned to either the sertraline with propranolol group (<jats:italic>n<\/jats:italic>\u2009=\u200930) or the sertraline with propranolol placebo group (<jats:italic>n<\/jats:italic>\u2009=\u200930) using block randomization method. Both groups received drugs for four weeks. Data were collected using the Panic Disorder Severity Scale\u2013 Self-Report (PDSS-SR) and the Beck Depression Inventory-Short Form (BDI-13). The Mann-Whitney U test was employed to compare outcomes between the two groups, and Wilcoxon tests were used for within-group comparisons.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Samples were enrolled from July 22, 2024, to February 11, 2025. The two groups exhibited no statistically significant differences in sociodemographic characteristics (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). After the intervention, the mean score for the severity of panic attack symptoms in the sertraline with propranolol group was 6.6 (SD: 4.4), compared to 13.1 (SD: 5.4) in the sertraline with propranolol placebo group, indicating a statistically significant difference (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Additionally, the mean (SD) post-intervention depression score was 8.9 (4.8) in the sertraline with propranolol group and 15.5 (7.2) in the sertraline with propranolol placebo group, with the sertraline with propranolol group demonstrating a significantly lower mean depression score according to the Mann-Whitney U test (<jats:italic>p<\/jats:italic>\u2009=\u20090.001). Within-group comparisons also revealed a significant reduction in the severity scores for both panic attack symptoms and depression in the sertraline with propranolol group (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Based on the results of this trial, using propranolol alongside sertraline reduces the severity of panic attacks. Given these promising results, further studies in various settings are recommended to provide high-certainty evidence in this field.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>Iranian Registry of Clinical Trials (IRCT): IRCT20120718010324N70. Date of registration: 2022-08-31; URL: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/irct.behdasht.gov.ir\/user\/trial\/65033\/view\" ext-link-type=\"uri\">https:\/\/irct.behdasht.gov.ir\/user\/trial\/65033\/view<\/jats:ext-link>.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40780-025-00466-x","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T18:27:37Z","timestamp":1751653657000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of sertraline with or without propranolol on panic attacks in women: a controlled clinical trial"],"prefix":"10.1186","volume":"11","author":[{"given":"Sahar","family":"Rouhzendeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sepideh","family":"Mashayekh-Amiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elnaz","family":"Shaseb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyedeh Tahereh","family":"Mirmolaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojgan","family":"Mirghafourvand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"466_CR1","volume-title":"Book review: diagnostic and statistical manual of mental disorders: (DSM-5)","author":"RN Kocsis","year":"2013","unstructured":"Kocsis RN. Book review: diagnostic and statistical manual of mental disorders: (DSM-5). Los Angeles, CA: In.: Sage Publications Sage CA; 2013."},{"key":"466_CR2","doi-asserted-by":"crossref","unstructured":"El Khoudary SR, Greendale G, Crawford SL, Avis NE, Brooks MM, Thurston RC, Karvonen-Gutierrez C, Waetjen LE, Matthews K. The menopause transition and women\u2019s health at midlife: a progress report from the Study of Women\u2019s Health Across the Nation (SWAN). Menopause (New York, NY) 2019, 26(10):1213\u20131227.","DOI":"10.1097\/GME.0000000000001424"},{"key":"466_CR3","unstructured":"Moghani SS, Simbar M, Fakari FR, Ghasemi V, Dolatian M, Golmakani N. Nasiri MJSJoHN, Faculty-ISSN M: The relationship between stress, anxiety and depression with menopausal women experiences. 2018, 2008:2819."},{"issue":"4","key":"466_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0165-0327(79)90014-4","volume":"1","author":"DL Pauls","year":"1979","unstructured":"Pauls DL, Noyes R Jr., Crowe RR. The Familial prevalence in second-degree relatives of patients with anxiety neurosis (panic disorder). J Affect Disord. 1979;1(4):279\u201385.","journal-title":"J Affect Disord"},{"key":"466_CR5","doi-asserted-by":"crossref","unstructured":"Smoller JW, Pollack MH, Wassertheil-Smoller S, Barton B, Hendrix SL, Jackson RD, Dicken T, Oberman A. Sheps DSJAoim: Prevalence and correlates of panic attacks in postmenopausal women: results from an ancillary study to the Women\u2019s Health Initiative. 2003, 163(17):2041\u201350.","DOI":"10.1001\/archinte.163.17.2041"},{"issue":"4","key":"466_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1001\/archpsyc.63.4.415","volume":"63","author":"RC Kessler","year":"2006","unstructured":"Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National comorbidity survey replication. Arch Gen Psychiatry. 2006;63(4):415\u201324.","journal-title":"Arch Gen Psychiatry"},{"key":"466_CR7","doi-asserted-by":"crossref","unstructured":"Guha MJRR. Diagnostic and statistical manual of mental disorders: DSM-5. 2014, 28(3):36\u201337.","DOI":"10.1108\/RR-10-2013-0256"},{"key":"466_CR8","doi-asserted-by":"crossref","unstructured":"Bentley KH, Franklin JC, Ribeiro JD, Kleiman EM, Fox KR. Nock mkjcpr: anxiety and its disorders as risk factors for suicidal thoughts and behaviors: A meta-analytic review. 2016, 43:30\u201346.","DOI":"10.1016\/j.cpr.2015.11.008"},{"key":"466_CR9","doi-asserted-by":"publisher","first-page":"595584","DOI":"10.3389\/fpsyt.2020.595584","volume":"11","author":"A Garakani","year":"2020","unstructured":"Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, Iosifescu DV. Pharmacotherapy of anxiety disorders: current and emerging treatment options. Front Psychiatry. 2020;11:595584.","journal-title":"Front Psychiatry"},{"key":"466_CR10","first-page":"e066084","volume":"376","author":"N Chawla","year":"2022","unstructured":"Chawla N, Anothaisintawee T, Charoenrungrueangchai K, Thaipisuttikul P, McKay GJ, Attia J, Thakkinstian A. Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. BMJ (Clinical Res ed). 2022;376:e066084.","journal-title":"BMJ (Clinical Res ed)"},{"key":"466_CR11","doi-asserted-by":"crossref","unstructured":"Kitaichi Y, Inoue T, Nakagawa S, Boku S, Kakuta A, Izumi T et al. Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. 2010;647(1\u20133):90\u20136.","DOI":"10.1016\/j.ejphar.2010.08.026"},{"key":"466_CR12","doi-asserted-by":"crossref","unstructured":"Sanchez C, Reines EH. Montgomery sajicp: A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? 2014, 29(4):185\u201396.","DOI":"10.1097\/YIC.0000000000000023"},{"key":"466_CR13","unstructured":"Rehsia NS, Dhalla NSJE, Cardiology C. Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure. 2010, 15(4):e86."},{"key":"466_CR14","doi-asserted-by":"crossref","unstructured":"Brudkowska \u017b, Tomczyk M, Jusiak K, Karaku\u0142a-Juchnowicz H. Rudnicka-Dro\u017cak ejcpop: the role of beta-adrenolytic drugs in treating anxiety disorders. 2018, 19(3):192\u2013208.","DOI":"10.2478\/cpp-2018-0017"},{"key":"466_CR15","doi-asserted-by":"crossref","unstructured":"Turner P, Granville-Grossman K, Smart JJTL. Effect of adrenergic receptor Blockade on the tachycardia of thyrotoxicosis and anxiety state. 1965, 286(7426):1316\u20138.","DOI":"10.1016\/S0140-6736(65)92340-8"},{"key":"466_CR16","doi-asserted-by":"crossref","unstructured":"Archer C, MacNeill SJ, Mars B, Turner K, Kessler D, Wiles NJBJGP. Rise in prescribing for anxiety in UK primary care between 2003 and 2018: a population-based cohort study using clinical practice research datalink. 2022, 72(720):e511\u20138.","DOI":"10.3399\/BJGP.2021.0561"},{"key":"466_CR17","doi-asserted-by":"crossref","unstructured":"Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD. Iosifescu DVJFip: Pharmacotherapy of anxiety disorders: current and emerging treatment options. 2020, 11:595584.","DOI":"10.3389\/fpsyt.2020.595584"},{"key":"466_CR18","unstructured":"British Columbia Health Link. (2022). Propranolol - Oral. Retrieved [https:\/\/www.healthlinkbc.ca\/medications\/propranolol-oral#:~:text=Use%20the%20drug%20for%20a,or%20overactive%20thyroid%20(hyperthyroidism).]."},{"key":"466_CR19","doi-asserted-by":"crossref","unstructured":"Steenen SA, Van Wijk AJ, Van Der Heijden GJ, van Westrhenen R, de Lange J. De Jongh ajjop: propranolol for the treatment of anxiety disorders: systematic review and meta-analysis. 2016, 30(2):128\u201339.","DOI":"10.1177\/0269881115612236"},{"key":"466_CR20","doi-asserted-by":"crossref","unstructured":"Szeleszczuk \u0141, Fr\u0105czkowski DJI. Propranolol versus other selected drugs in the treatment of various types of anxiety or stress, with particular reference to stage fright and post-traumatic stress disorder. 2022, 23(17):10099.","DOI":"10.3390\/ijms231710099"},{"key":"466_CR21","doi-asserted-by":"crossref","unstructured":"Archer C, Wiles N, Kessler D, Turner K, Caldwell DMJJAD. Beta-blockers for the treatment of anxiety disorders: a systematic review and meta-analysis. 2024.","DOI":"10.1016\/j.jad.2024.09.068"},{"key":"466_CR22","doi-asserted-by":"crossref","unstructured":"Houck PR, Spiegel DA, Shear MK, Rucci PJD. anxiety: Reliability of the self-report version of the panic disorder severity scale. 2002, 15(4):183\u2013185.","DOI":"10.1002\/da.10049"},{"key":"466_CR23","doi-asserted-by":"crossref","unstructured":"Beck AT, Beck RWJP. Screening depressed patients in family practice: A rapid technic. 1972, 52(6):81\u20135.","DOI":"10.1080\/00325481.1972.11713319"},{"key":"466_CR24","unstructured":"Rajabi GRJJIP. Psychometric properties of beck depression inventory short form items (BDI-13). 2004."},{"key":"466_CR25","doi-asserted-by":"crossref","unstructured":"Forsell E, Kraepelien M, Blom K, Isacsson N, Jernel\u00f6v S, Svanborg C, Ros\u00e9n A, Kaldo VJJAD. Development of a very brief scale for detecting and measuring panic disorder using two items from the panic disorder severity Scale-Self report. 2019, 257:615\u201322.","DOI":"10.1016\/j.jad.2019.07.057"},{"issue":"12","key":"466_CR26","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1001\/archpsyc.1980.01780250047005","volume":"37","author":"RG Kathol","year":"1980","unstructured":"Kathol RG, Noyes R Jr., Slymen DJ, Crowe RR, Clancy J, Kerber RE. Propranolol in chronic anxiety disorders. A controlled study. Arch Gen Psychiatry. 1980;37(12):1361\u20135.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"466_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/00004714-198902000-00005","volume":"9","author":"DJ Munjack","year":"1989","unstructured":"Munjack DJ, Crocker B, Cabe D, Brown R, Usigli R, Zulueta A, McManus M, McDowell D, Palmer R, Leonard M. Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol. 1989;9(1):22\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"466_CR28","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1001\/archpsyc.1980.01780250047005","volume":"37","author":"RG Kathol","year":"1980","unstructured":"Kathol RG, Noyes R, Slymen DJ, Crowe RR, Clancy J, Kerber RE. Propranolol in chronic anxiety disorders: A controlled study. Arch Gen Psychiatry. 1980;37(12):1361\u20135.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"466_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/archpsyc.1984.01790140077009","volume":"41","author":"R Noyes Jr","year":"1984","unstructured":"Noyes R Jr., Anderson DJ, Clancy J, Crowe RR, Slymen DJ, Ghoneim MM, et al. Diazepam and propranolol in panic disorder and agoraphobia. Arch Gen Psychiatry. 1984;41(3):287\u201392. https:\/\/doi.org\/10.1001\/archpsyc.1984.01790140077009. Epub 1984\/03\/01.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"466_CR30","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/00004714-199112000-00003","volume":"11","author":"CL Ravaris","year":"1991","unstructured":"Ravaris CL, Friedman MJ, Hauri PJ, McHugo GJ. A controlled study of Alprazolam and propranolol in panic-disordered and agoraphobic outpatients. J Clin Psychopharmacol. 1991;11(6):344\u201350. Epub 1991\/12\/01. PubMed PMID: 1770152.","journal-title":"J Clin Psychopharmacol"},{"key":"466_CR31","doi-asserted-by":"crossref","unstructured":"Dooley TPJMHFM. Treating anxiety with either beta blockers or antiemetic antimuscarinic drugs: a review. 2015, 11(02):89\u201399.","DOI":"10.25149\/1756-8358.1102013"},{"key":"466_CR32","doi-asserted-by":"crossref","unstructured":"Hirschmann S, Dannon PN, Iancu I, Dolberg OT, Zohar J, Grunhaus L. Pindolol augmentation in patients with Treatment-Resistant panic disorder: A Double-Blind, Placebo-Controlled trial. J Clin Psychopharmacol 2000, 20(5).","DOI":"10.1097\/00004714-200010000-00011"},{"key":"466_CR33","doi-asserted-by":"crossref","unstructured":"Stein MB, Sareen J, Hami S, Chao JJAJP. Pindolol potentiation of Paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. 2001, 158(10):1725\u20137.","DOI":"10.1176\/appi.ajp.158.10.1725"},{"key":"466_CR34","doi-asserted-by":"crossref","unstructured":"Archer C, Kessler D, Wiles N, Chew-Graham CA, Turner KJBJGP. Exploring GPs\u2019 views on beta-blocker prescribing for people with anxiety disorders: a qualitative study. 2024.","DOI":"10.3399\/BJGP.2024.0091"},{"issue":"7426","key":"466_CR35","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/S0140-6736(65)92340-8","volume":"286","author":"P Turner","year":"1965","unstructured":"Turner P, Granville-Grossman K, Smart J. Effect of adrenergic receptor Blockade on the tachycardia of thyrotoxicosis and anxiety state. Lancet. 1965;286(7426):1316\u20138.","journal-title":"Lancet"},{"issue":"5451","key":"466_CR36","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1126\/science.287.5451.248","volume":"287","author":"JL McGaugh","year":"2000","unstructured":"McGaugh JL. Memory\u2013a century of consolidation. Science. 2000;287(5451):248\u201351.","journal-title":"Science"},{"issue":"6499","key":"466_CR37","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/371702a0","volume":"371","author":"L Cahill","year":"1994","unstructured":"Cahill L, Prins B, Weber M, McGaugh JL. \u03b2-Adrenergic activation and memory for emotional events. Nature. 1994;371(6499):702\u20134.","journal-title":"Nature"},{"issue":"3","key":"466_CR38","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.neuroimage.2004.09.011","volume":"24","author":"AH Van Stegeren","year":"2005","unstructured":"Van Stegeren AH, Goekoop R, Everaerd W, Scheltens P, Barkhof F, Kuijer JP, Rombouts SA. Noradrenaline mediates amygdala activation in men and women during encoding of emotional material. NeuroImage. 2005;24(3):898\u2013909.","journal-title":"NeuroImage"},{"issue":"31","key":"466_CR39","doi-asserted-by":"publisher","first-page":"11454","DOI":"10.1073\/pnas.0404282101","volume":"101","author":"B Strange","year":"2004","unstructured":"Strange B. R Dolan 2004 \u03b2-Adrenergic modulation of emotional memory-evoked human amygdala and hippocampal responses. Proc Natl Acad Sci 101 31 11454\u20138.","journal-title":"Proc Natl Acad Sci"},{"issue":"11","key":"466_CR40","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1017\/S0033291709992376","volume":"40","author":"R Hurlemann","year":"2010","unstructured":"Hurlemann R, Walter H, Rehme A, Kukolja J, Santoro S, Schmidt C, Schnell K, Musshoff F, Keysers C, Maier W. Human amygdala reactivity is diminished by the \u03b2-noradrenergic antagonist propranolol. Psychol Med. 2010;40(11):1839\u201348.","journal-title":"Psychol Med"},{"issue":"6","key":"466_CR41","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1162\/jocn_a_00941","volume":"28","author":"U Rimmele","year":"2016","unstructured":"Rimmele U, Lackovic SF, Tobe RH, Leventhal BL, Phelps EA. Beta-adrenergic Blockade at memory encoding, but not retrieval, decreases the subjective sense of recollection. J Cogn Neurosci. 2016;28(6):895\u2013907.","journal-title":"J Cogn Neurosci"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00466-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00466-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00466-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T18:27:41Z","timestamp":1751653661000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-025-00466-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["466"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00466-x","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was approved by the Committee of Medical Ethics of Tabriz University of Medical Sciences (Ethical code: IR.TBZMED.REC.1401.341) and registered at the Iranian Center for Clinical Trial with the IRCT20120718010324N70 code (31\/08\/2022). We obtained informed written consent from all participants before their recruitment. We designed and conducted this study following the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}